Chemotherapy in patients with inoperable or advanced breast cancer inevitably results in low-dose exposure of tumor-cell subset and senescence. Metabolically active senescent cells secrete multiple tumor promoting factors making their elimination a therapeutic priority. Viscum album is one of the most widely used alternative anti-cancer medicines facilitating chemotherapy tolerance of breast cancer patients. The aim of this study was to model and investigate how Viscum album extracts execute additive anti-tumor activity with low-dose Dox using ER + MCF7 breast cancer cells. We report that cotreatment of MCF7 with Viscum album and Dox abrogates G2/M cycle arrest replacing senescence with intrinsic apoptotic program. Mechanistically, this switch was associated with down-regulation of p21, p53/p73 as well as Erk1/2 and p38 activation. Our findings, therefore, identify a novel mechanistic axis of additive antitumor activity of Viscum album and low dose-Dox. In conclusion, ER + breast cance...r patients may benefit from addition of Viscum album to low-dose Dox chemotherapy due to suppression of cancer cell senescence and induction of apoptosis.
TY - JOUR
AU - Srdić-Rajić, Tatjana
AU - Santibanez, Juan
AU - Kanjer, Ksenija
AU - Tišma-Miletić, Nevena
AU - Cavić, Milena
AU - Galun, Daniel
AU - Jevrić, Marko
AU - Kardum, Nevena Đ.
AU - Konić-Ristić, Aleksandra
AU - Zoranović, Tamara
PY - 2017
UR - http://rimi.imi.bg.ac.rs/handle/123456789/819
AB - Chemotherapy in patients with inoperable or advanced breast cancer inevitably results in low-dose exposure of tumor-cell subset and senescence. Metabolically active senescent cells secrete multiple tumor promoting factors making their elimination a therapeutic priority. Viscum album is one of the most widely used alternative anti-cancer medicines facilitating chemotherapy tolerance of breast cancer patients. The aim of this study was to model and investigate how Viscum album extracts execute additive anti-tumor activity with low-dose Dox using ER + MCF7 breast cancer cells. We report that cotreatment of MCF7 with Viscum album and Dox abrogates G2/M cycle arrest replacing senescence with intrinsic apoptotic program. Mechanistically, this switch was associated with down-regulation of p21, p53/p73 as well as Erk1/2 and p38 activation. Our findings, therefore, identify a novel mechanistic axis of additive antitumor activity of Viscum album and low dose-Dox. In conclusion, ER + breast cancer patients may benefit from addition of Viscum album to low-dose Dox chemotherapy due to suppression of cancer cell senescence and induction of apoptosis.
PB - Nature Publishing Group, London
T2 - Scientific Reports
T1 - Iscador Qu inhibits doxorubicin-induced senescence of MCF7 cells
SP - 3763
VL - 7
DO - 10.1038/s41598-017-03898-0
UR - conv_4045
ER -
@article{
author = "Srdić-Rajić, Tatjana and Santibanez, Juan and Kanjer, Ksenija and Tišma-Miletić, Nevena and Cavić, Milena and Galun, Daniel and Jevrić, Marko and Kardum, Nevena Đ. and Konić-Ristić, Aleksandra and Zoranović, Tamara",
year = "2017",
abstract = "Chemotherapy in patients with inoperable or advanced breast cancer inevitably results in low-dose exposure of tumor-cell subset and senescence. Metabolically active senescent cells secrete multiple tumor promoting factors making their elimination a therapeutic priority. Viscum album is one of the most widely used alternative anti-cancer medicines facilitating chemotherapy tolerance of breast cancer patients. The aim of this study was to model and investigate how Viscum album extracts execute additive anti-tumor activity with low-dose Dox using ER + MCF7 breast cancer cells. We report that cotreatment of MCF7 with Viscum album and Dox abrogates G2/M cycle arrest replacing senescence with intrinsic apoptotic program. Mechanistically, this switch was associated with down-regulation of p21, p53/p73 as well as Erk1/2 and p38 activation. Our findings, therefore, identify a novel mechanistic axis of additive antitumor activity of Viscum album and low dose-Dox. In conclusion, ER + breast cancer patients may benefit from addition of Viscum album to low-dose Dox chemotherapy due to suppression of cancer cell senescence and induction of apoptosis.",
publisher = "Nature Publishing Group, London",
journal = "Scientific Reports",
title = "Iscador Qu inhibits doxorubicin-induced senescence of MCF7 cells",
pages = "3763",
volume = "7",
doi = "10.1038/s41598-017-03898-0",
url = "conv_4045"
}
Srdić-Rajić, T., Santibanez, J., Kanjer, K., Tišma-Miletić, N., Cavić, M., Galun, D., Jevrić, M., Kardum, N. Đ., Konić-Ristić, A.,& Zoranović, T.. (2017). Iscador Qu inhibits doxorubicin-induced senescence of MCF7 cells. in Scientific Reports
Nature Publishing Group, London., 7, 3763.
https://doi.org/10.1038/s41598-017-03898-0
conv_4045
Srdić-Rajić T, Santibanez J, Kanjer K, Tišma-Miletić N, Cavić M, Galun D, Jevrić M, Kardum NĐ, Konić-Ristić A, Zoranović T. Iscador Qu inhibits doxorubicin-induced senescence of MCF7 cells. in Scientific Reports. 2017;7:3763.
doi:10.1038/s41598-017-03898-0
conv_4045 .
